Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012.

For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011. For the year ended December 31, 2012, the Company reported net income of $5.0 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30.0 million during 2011 were primarily responsible for the change in operating results year over year.

The Company's balance sheet at December 31, 2012 reflected total assets of $196.0 million, including cash, investments and receivables of $188.3 million compared with balances at December 31, 2011 of $138.4 million and $131.7 million, respectively.  During January 2012, the Company completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83.0 million.

"During 2012 we continued to perform to financial plan and were successful in moving our VMAT2 tardive dyskinesia program forward, as well as AbbVie advancing the elagolix endometriosis and uterine fibroids programs," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences. "Looking to 2013 we will have two Phase IIb readouts for our VMAT2 program, expect AbbVie to progress elagolix into Phase IIb in uterine fibroids, and we anticipate one additional program entering the clinic, resulting in a very productive year."

Revenues for the fourth quarter of 2012 were $21.9 million, compared to $11.1 million for the same period in 2011. The $10.8 million increase in revenue is primarily due to higher rev
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... China, FORT LAUDERDALE, Fla., Sept. 5 ... pioneer in laser,optical breast cancer imaging systems, has ... Tianjin Medical University,s Cancer Institute and,Hospital, the largest ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) Research at the Cancer ...
... EDMONTON, Sept. 5 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: ... of three-year survival results,from a randomized Phase II ... lung cancer (NSCLC). The results suggest that Stimuvax,combined ... benefits to,patients with unresectable stage IIIB NSCLC who ...
... FRANCISCO, Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical ... and hepatology therapies for the,treatment of Urea Cycle ... $40 million Series B financing. Leading the round ... Partners and,NEA, all of Menlo Park, CA. WRF ...
Cached Biology Technology:Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 2Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... groups and clinicians is critical to the development ... of Georgia research. , A qualitative study of ... that role models for successful breastfeeding help positively ... "Mothers who received that support are more likely ... Alex Anderson, an associate professor in the College ...
(Date:8/28/2014)... complex systems. Their infrastructure equipment requires ancillary sub-systems ... to supply fuel, and ICT systems for control ... is interconnected with a wider network and they ... scientists has studied various aspects of inter-network dependencies, ... in EPJ B by Gaihua Fu from Newcastle ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2Inter-dependent networks stress test 2
... by Dr. Ann F. Jacobson, associate professor in Kent ... may initially choose to postpone but ultimately undergo total ... patient education before and after the procedure. ... pre-and post operative experiences with total knee replacement surgery, ...
... release is available in Spanish . , A ... (USA) and Nakai (China), among others, have deciphered for the first ... to the cover of the last issue of the prestigious journal ... to the group of Molecular Genetics of the Department of ...
... fund four faculty research projects for spring 2008. ... a number of excellent proposals submitted in response ... for the program is administered by the OSU ... by royalties from OSU-licensed technologies. These funded projects ...
Cached Biology News:Research examines factors in delaying or declining total knee replacement surgery 2Scientists decipher fruit tree genome for the first time 2Scientists decipher fruit tree genome for the first time 3OSU technologies funded for development 2OSU technologies funded for development 3
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
Biology Products: